Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 9/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 6/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 6/20 | 0.36 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ROS1 | P08922 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302987 | 0.91 | PRKAB2 (0.42) | TGFBR1TNFSUV39H2KMT2AHSD17B10 | |
| SCHEMBL2300656 | 0.90 | TGFBR1 (0.40) | ACVR1TGFBR1TNFKMT2AHSD17B10 | |
| SCHEMBL2301546 | 0.89 | ACVR1 (0.40) | ACVR1TGFBR1CYP1A1TNFRIPK2 | |
| SCHEMBL2302556 | 0.87 | ACVR1 (0.43) | ACVR1TGFBR1CYP1A1RIPK2SUV39H2 | |
| SCHEMBL2304343 | 0.85 | CCNA2 (0.33) | SUV39H2EGFRROS1ALKKMT2A | |
| SCHEMBL2299984 | 0.84 | TGFBR1 (0.40) | ACVR1TGFBR1SUV39H2EGFRROS1 | |
| SCHEMBL14119235 | 0.84 | DGAT2 (0.40) | ACVR1TGFBR1KMT2AHSD17B10 | |
| SCHEMBL2304872 | 0.84 | KMT2A (0.38) | EGFRROS1ALKKMT2A | |
| SCHEMBL2299608 | 0.83 | ALOX5 (0.39) | — | |
| SCHEMBL2301831 | 0.82 | MEN1 (0.36) | CYP1A1SUV39H2ADRB1EGFRROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034888-B2 | Substituted 2-imidazolidones and analogs | UNIVERSITE LAVAL (CA) | 2015-05-19 | — | — | US | disclosed |
| EP-2536693-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | Université Laval (CA) | 2012-12-26 | — | — | EP | disclosed |
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITE LAVAL (CA) | 2012-12-06 | — | — | US | disclosed |
| WO-2011100840-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITé LAVAL (CA) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | CCNY, RPS4Y1, TPX2 | ACVR1 1246/4885TGFBR1 2246/4885CYP1A1 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.